Pannexin 1 channel blockers

Blocking multiple pathways to transform
cancer therapy

PANNEX Therapeutics is pioneering the development of Pannexin 1 channel (Panx1) blockers, a new class of cancer drugs that block multiple pathways to stop growth, spread and survival of cancer cells.

Learn more

Discover our science

Pannexin 1

The Pannexin 1 channel (Panx1) is a recently discovered and validated pharmacological target that plays a key role in multiple pathophysiological pathways of many types of cancer.


Our team

David Bravo PhD

Chief Executive Officer &

Pannexin 1 research leader with more than a decade of success in drug discovery and innovation

Thomas Gerlach PhD

Chief Strategic Officer &

Biochemist with over 30 years of experience in global drug development, commercialization and venture capital

Gerhard Gross PhD

Chief Scientific Officer &

Chemist with 30 years of experience in drug discovery and development - 14 FDA - approved drugs